Overview of The Tim Ferriss Show Episode #883
Tim Ferriss interviews Tania de Jong, co-founder of Mind Medicine Australia, about how she and her husband Peter helped make Australia the first country in the world to allow MDMA and psilocybin to be prescribed for certain psychiatric conditions. The conversation focuses less on psychedelics as a topic and more on the playbook for creating large-scale change: building coalitions, navigating regulators, mobilizing public support, recruiting experts, and persisting through rejection.
Tania shares how a deeply personal psychedelic experience led her from newcomer to policy advocate, and how a mix of storytelling, data, clinician training, public pressure, and strategic lobbying helped create a real-world rollout in Australia.
Key Takeaways
-
Personal experience became the catalyst
- Tania had no prior background in psychedelics, but after reading Michael Pollan’s “The Trip Treatment,” she and Peter pursued psilocybin experiences in Europe.
- The experience was described as life-changing, relationally healing, and spiritually profound.
- That led them to ask: if this helps us, how can it help people with trauma, depression, addiction, and other forms of suffering?
-
Australia’s breakthrough was not luck — it was a campaign
- Mind Medicine Australia launched in 2019 and pushed for rescheduling of MDMA and psilocybin from prohibited substances to controlled medicines.
- The campaign involved:
- repeated submissions to the TGA (Australia’s regulator, analogous to the FDA),
- public education,
- clinician training,
- outreach to politicians and health professionals,
- and a large-scale public submission effort.
-
Public pressure mattered
- The final TGA submission drew 13,000+ public responses, with over 98% support for rescheduling.
- Tania emphasized that this was the largest public submission volume ever received by the regulator for a medicine rescheduling decision.
-
Expert allies were crucial
- They recruited prominent figures such as:
- Rick Doblin
- Roland Griffiths
- Robin Carhart-Harris
- David Nutt
- Bill Linton
- A world-leading advisory panel of about 75 experts helped legitimize the effort and guide strategy.
- They recruited prominent figures such as:
-
The emotional, human side moved regulators
- A pivotal TGA meeting featured testimony from Vanessa, whose husband Franco died after severe depression and failed treatments.
- Her story, paired with scientific evidence from David Nutt, helped make the case that not acting also carries risk.
-
The rollout is now real, not theoretical
- Australia now has:
- 120 authorized prescribing psychiatrists (as stated in the conversation),
- 20+ clinics,
- and roughly 400 patients treated.
- Reported outcomes are strong: 60–80% remission rates in their real-world experience, with no serious adverse events reported in the conversation.
- Australia now has:
Strategy Playbook: What Actually Worked
1) Build a movement, not just a campaign
Mind Medicine Australia didn’t rely on one tactic. It created a full ecosystem:
- public education
- clinician education
- advisory panel
- local chapters
- government engagement
- payer engagement
- patient support funds
- research registry
2) Make it easy for supporters to act
Tania described using:
- templates
- precedents
- clear instructions for submissions
- local chapter leaders
- ready-made advocacy materials
This made it simple for volunteers and supporters to help at scale.
3) Combine science with stories
The campaign worked because it paired:
- rigorous evidence and expert voices
- with real patient stories that made the stakes emotionally undeniable
4) Train the workforce before the doors open
They began training clinicians in 2021 through a certificate program in psychedelic-assisted therapy, so when regulations changed, there were already qualified professionals ready to deliver care.
5) Engage payers early
They approached funders and insurers early, including:
- Department of Veterans Affairs
- National Disability Insurance Scheme (NDIS)
- Medibank
This helped reduce the biggest barrier: upfront cost.
Current Model in Australia
- Treatments are delivered in clinics, not casually or underground.
- Sessions include:
- careful screening
- preparation
- dosing with two therapists
- integration over 3–4 months
- The medicines themselves are relatively inexpensive; most of the cost is therapeutic time.
- A typical course was described as roughly:
- AUD $8,000 for an initial treatment pathway
- up to around AUD $25,000 for a fuller course with multiple doses and integration
Challenges and Mistakes
Tania was candid about what was hard:
-
Vested interests in the research ecosystem
- Some researchers wanted to keep studying for years before access changed.
- MMA argued that people were suffering now and needed options now.
-
Skepticism toward non-clinicians
- As entrepreneurs, not doctors, Tania and Peter faced resistance from some medical professionals and academics.
-
Hiring challenges
- They initially brought on people whose own unresolved issues made high-pressure advocacy work difficult.
-
Over-pushing
- Tania admitted she can be too forceful and has learned to temper that.
- Still, she believes persistence was necessary in this campaign.
Psychedelic-Specific Discussion Points
-
MDMA vs. psilocybin
- MDMA was often easier for clinicians to start with.
- Psilocybin is increasingly being explored for broader indications.
-
Integration matters
- Tania and Tim discussed the importance of:
- therapy,
- nutrition,
- exercise,
- social connection,
- and behavior change after the experience.
- Tania and Tim discussed the importance of:
-
Group settings may be powerful
- Tim noted that group integration can be more cost-effective and potentially better for outcomes and meaning-making.
-
Ketamine was discussed as a comparison
- Tim shared caution about ketamine’s abuse potential and noted that while it can help in some contexts, he would not rank it among top options for many people.
- The conversation contrasted ketamine’s model with more durable psychedelic-assisted therapy approaches.
Personal and Spiritual Themes
Tania emphasized that these medicines helped her:
- release control
- deepen her connection to nature
- strengthen her marriage
- become more curious and reflective
- access meditative states more easily
A recurring theme was the idea that psychedelics can help people “come home” to themselves.
Notable lines/themes from the episode:
- “We’re all walking each other home.” — Ram Dass
- “Be curious.”
- The importance of not outsourcing all thinking or self-understanding to systems or technology
Calls to Action / Resources
Tania shared a few specific asks:
-
Donate to the patient support fund
- Goal mentioned: AUD $2.5 million
- Purpose: help veterans, first responders, single mothers, and others who cannot afford treatment
-
Clinicians and therapists
- Apply for or learn from the Certificate in Psychedelic-Assisted Therapies
- Next intakes mentioned: February and July 2027
-
Learn more / get involved
- Main site: mindmedicinaustralia.org.au
- Personal site: taniadejong.com
Bottom Line
This episode is both a psychedelic-policy case study and a masterclass in advocacy. The core lesson is that major change can happen when you combine:
- personal conviction
- expert alliances
- public education
- patient stories
- persistent regulator engagement
- and a systems approach to implementation
Tania de Jong’s story shows that outsiders can help reshape a national medical landscape — if they’re willing to do the hard, unglamorous work for years.